Skip Navigation


Annals of Oncology Advance Access originally published online on October 16, 2006
Annals of Oncology 2006 17(11):1609; doi:10.1093/annonc/mdl405
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/11/1609    most recent
mdl405v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer
 
Endocrine sensitivity of breast cancer, assessed by the expression of the estrogen (ER) and/or progesterone (PR) receptors, has long been the only recognized and validated predictive factor to guide therapeutic decisions. More recently, the overexpression of the HER-2 (c-erbB-2/neu) oncogene has been recognized as a significant variable for the assessment of breast cancer prognosis and response to treatments in the metastatic and adjuvant settings. According . . . [Full Text of this Article]


   Predicting survival of patients with colorectal cancer with FDG-PET
 

   Mantle irradiation alone for early-stage Hodgkin's disease
 

   Health-related quality of life in lung cancer
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?